BMNDF
Price
$0.70
Change
+$0.39 (+125.81%)
Updated
Jan 13 closing price
Capitalization
16.16M
RGLS
Price
$1.24
Change
-$0.04 (-3.12%)
Updated
Jan 17 closing price
Capitalization
81.22M
60 days until earnings call
Ad is loading...

BMNDF vs RGLS

Header iconBMNDF vs RGLS Comparison
Open Charts BMNDF vs RGLSBanner chart's image
BIOMIND LABS
Price$0.70
Change+$0.39 (+125.81%)
Volume$800
Capitalization16.16M
Regulus Therapeutics
Price$1.24
Change-$0.04 (-3.12%)
Volume$330.14K
Capitalization81.22M
BMNDF vs RGLS Comparison Chart
Loading...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMNDF vs. RGLS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMNDF is a Hold and RGLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (BMNDF: $0.70 vs. RGLS: $1.24)
Brand notoriety: BMNDF and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMNDF: 12% vs. RGLS: 114%
Market capitalization -- BMNDF: $16.16M vs. RGLS: $81.22M
BMNDF [@Biotechnology] is valued at $16.16M. RGLS’s [@Biotechnology] market capitalization is $81.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $352.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMNDF’s FA Score shows that 0 FA rating(s) are green whileRGLS’s FA Score has 1 green FA rating(s).

  • BMNDF’s FA Score: 0 green, 5 red.
  • RGLS’s FA Score: 1 green, 4 red.
According to our system of comparison, both BMNDF and RGLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGLS’s TA Score shows that 4 TA indicator(s) are bullish.

  • RGLS’s TA Score: 4 bullish, 5 bearish.

Price Growth

BMNDF (@Biotechnology) experienced а +127.57% price change this week, while RGLS (@Biotechnology) price change was -12.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

RGLS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGLS($81.2M) has a higher market cap than BMNDF($16.2M). BMNDF YTD gains are higher at: 127.568 vs. RGLS (-21.519). BMNDF has higher annual earnings (EBITDA): -314.15K vs. RGLS (-41.03M). RGLS has more cash in the bank: 87.3M vs. BMNDF (10.1K). RGLS has less debt than BMNDF: RGLS (476K) vs BMNDF (883K). BMNDF (0) and RGLS (0) have equivalent revenues.
BMNDFRGLSBMNDF / RGLS
Capitalization16.2M81.2M20%
EBITDA-314.15K-41.03M1%
Gain YTD127.568-21.519-593%
P/E RatioN/AN/A-
Revenue00-
Total Cash10.1K87.3M0%
Total Debt883K476K186%
FUNDAMENTALS RATINGS
BMNDF vs RGLS: Fundamental Ratings
BMNDF
RGLS
OUTLOOK RATING
1..100
4558
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3464
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGLS's Valuation (20) in the Pharmaceuticals Other industry is significantly better than the same rating for BMNDF (96) in the null industry. This means that RGLS’s stock grew significantly faster than BMNDF’s over the last 12 months.

BMNDF's Profit vs Risk Rating (61) in the null industry is somewhat better than the same rating for RGLS (100) in the Pharmaceuticals Other industry. This means that BMNDF’s stock grew somewhat faster than RGLS’s over the last 12 months.

RGLS's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as BMNDF (100) in the null industry. This means that RGLS’s stock grew similarly to BMNDF’s over the last 12 months.

BMNDF's Price Growth Rating (34) in the null industry is in the same range as RGLS (64) in the Pharmaceuticals Other industry. This means that BMNDF’s stock grew similarly to RGLS’s over the last 12 months.

BMNDF's P/E Growth Rating (100) in the null industry is in the same range as RGLS (100) in the Pharmaceuticals Other industry. This means that BMNDF’s stock grew similarly to RGLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGLS
RSI
ODDS (%)
Bullish Trend 6 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
90%
Momentum
ODDS (%)
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 25 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
89%
View a ticker or compare two or three
Ad is loading...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
BTC.X104408.070000-53.968750
-0.05%
Bitcoin cryptocurrency
GME27.51-0.21
-0.76%
GameStop Corp

BMNDF and

Correlation & Price change

A.I.dvisor tells us that BMNDF and CLVLY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMNDF and CLVLY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMNDF
1D Price
Change %
BMNDF100%
N/A
CLVLY - BMNDF
26%
Poorly correlated
-0.55%
RGLS - BMNDF
24%
Poorly correlated
-3.12%
MLLCF - BMNDF
21%
Poorly correlated
N/A
FRES - BMNDF
20%
Poorly correlated
N/A
VIGL - BMNDF
20%
Poorly correlated
+2.12%
More

RGLS and

Correlation & Price change

A.I.dvisor tells us that RGLS and NAUT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGLS and NAUT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
-3.12%
NAUT - RGLS
27%
Poorly correlated
+1.58%
SPRY - RGLS
26%
Poorly correlated
+3.20%
SLNCF - RGLS
25%
Poorly correlated
-8.26%
EYPT - RGLS
25%
Poorly correlated
+2.89%
CGEM - RGLS
25%
Poorly correlated
+1.18%
More